EGI
APRE icon

EAM Global Investors’s Aprea Therapeutics APRE Stock Holding History

EAM Global Investors’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,914
Closed -$1.33M – 120
2020
Q1 		$1.33M Buy
+1,914
New +$1.4M 0.78% 64

Other funds holding APRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM Global Investors's APRE Position: Q2 2020 in Review

EAM Global Investors sold out of Aprea Therapeutics (APRE) in Q2 2020, closing a stake of 1,914 shares — an estimated $1.33M sold.

EAM Global Investors first reported a position in APRE in Q1 2020 and held it in 1 quarter. The position peaked at $1.33M in Q1 2020. 64 funds tracked by Wall St. Rank hold APRE as of Q2 2020.

  • EAM Global Investors reported no remaining Aprea Therapeutics position as of Q2 2020 after selling out during the quarter.
  • EAM Global Investors sold 1,914 Aprea Therapeutics shares in Q2 2020, an estimated $1.33M.
  • EAM Global Investors first reported a position in Aprea Therapeutics in Q1 2020 and held it in 1 quarter.
  • EAM Global Investors's Aprea Therapeutics position peaked at $1.33M in Q1 2020.
  • 64 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2020.

Based on EAM Global Investors's 13F filing for Q2 2020, filed 13 Aug 2020.